Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin and Cardiac Remodelling in People Without Diabetes

X
Trial Profile

Empagliflozin and Cardiac Remodelling in People Without Diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Left ventricular hypertrophy; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms EMPA-HEART 2; EMPA-HEART 2 CardioLink-7
  • Most Recent Events

    • 13 Nov 2023 Results determining if Sodium-glucose co-transporter 2 (SGLT2) inhibition with empagliflozin leads to change in blood FABP4 levels and improvement in body composition in patients without diabetes and significant heart failure but with risk factors for adverse cardiac remodeling, presented at the American Heart Association Scientific Sessions 2023
    • 06 Mar 2023 Results of sub-study assessing to determine if EMPA modulates RCE in people without T2D who are at elevated cardiovascular (CV) risk, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
    • 16 Feb 2023 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top